{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:36:18Z","timestamp":1785443778970,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,5,27]],"date-time":"2012-05-27T00:00:00Z","timestamp":1338076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,5,27]],"date-time":"2012-05-27T00:00:00Z","timestamp":1338076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/nm.2763","type":"journal-article","created":{"date-parts":[[2012,5,27]],"date-time":"2012-05-27T18:31:13Z","timestamp":1338143473000},"page":"974-979","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Development of a new hydrogen peroxide\u2013based vaccine platform"],"prefix":"10.1038","volume":"18","author":[{"given":"Ian J","family":"Amanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Rau\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,27]]},"reference":[{"key":"BFnm2763_CR1","doi-asserted-by":"crossref","unstructured":"Plotkin, S.L. & Plotkin, S.A. A short history of vaccination. in Vaccines (eds. Plotkin, S.A., Orenstein, W.A. & Offit, P.A.) 1\u201316 (Saunders\/Elsevier, Philadelphia, 2008).","DOI":"10.1016\/B978-1-4160-3611-1.50005-2"},{"key":"BFnm2763_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4049\/jimmunol.75.2.123","volume":"75","author":"GA Logrippo","year":"1955","unstructured":"Logrippo, G.A. & Hartman, F.W. Antigenicity of \u03b2-propiolactone\u2013inactivated virus vaccines. J. Immunol. 75, 123\u2013128 (1955).","journal-title":"J. Immunol."},{"key":"BFnm2763_CR3","first-page":"103","volume":"81","author":"F Brown","year":"1993","unstructured":"Brown, F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 81, 103\u2013107 (1993).","journal-title":"Dev. Biol. Stand."},{"key":"BFnm2763_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H.W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"BFnm2763_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nm.1894","volume":"15","author":"MF Delgado","year":"2009","unstructured":"Delgado, M.F. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15, 34\u201341 (2009).","journal-title":"Nat. Med."},{"key":"BFnm2763_CR6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1542\/peds.70.2.203","volume":"70","author":"D Annunziato","year":"1982","unstructured":"Annunziato, D. et al. Atypical measles syndrome: pathologic and serologic findings. Pediatrics 70, 203\u2013209 (1982).","journal-title":"Pediatrics"},{"key":"BFnm2763_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/157489106778777673","volume":"1","author":"F Stauffer","year":"2006","unstructured":"Stauffer, F., El-Bacha, T. & Da Poian, A.T. Advances in the development of inactivated virus vaccines. Recent Pat. Antiinfect. Drug Disc. 1, 291\u2013296 (2006).","journal-title":"Recent Pat. Antiinfect. Drug Disc."},{"key":"BFnm2763_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/infdis\/155.5.909","volume":"155","author":"MC Swanson","year":"1987","unstructured":"Swanson, M.C. et al. IgE and IgG antibodies to \u03b2-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J. Infect. Dis. 155, 909\u2013913 (1987).","journal-title":"J. Infect. Dis."},{"key":"BFnm2763_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","volume":"364","author":"TP Monath","year":"2011","unstructured":"Monath, T.P. et al. An inactivated cell-culture vaccine against yellow fever. N. Engl. J. Med. 364, 1326\u20131333 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnm2763_CR10","unstructured":"Guenter, T.E. Hydrogen peroxide. in Encyclopedia of Chemical Processing and Design, Vol. 27 (ed. McKetta, J.J.) 27\u201343 (Marcel Dekker, New York, 1988)."},{"key":"BFnm2763_CR11","unstructured":"Sykes, G. The theory and mode of action of disinfection. in Disinfection and Sterilization, Ch. 2 (Lippincott, Philadelphia, 1965)."},{"key":"BFnm2763_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","volume":"39","author":"M Valko","year":"2007","unstructured":"Valko, M. et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44\u201384 (2007).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnm2763_CR13","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0264-410X(91)90289-I","volume":"9","author":"GR Siber","year":"1991","unstructured":"Siber, G.R. et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 9, 735\u2013740 (1991).","journal-title":"Vaccine"},{"key":"BFnm2763_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0027-5107(00)00019-1","volume":"450","author":"J Termini","year":"2000","unstructured":"Termini, J. Hydroperoxide-induced DNA damage and mutations. Mutat. Res. 450, 107\u2013124 (2000).","journal-title":"Mutat. Res."},{"key":"BFnm2763_CR15","doi-asserted-by":"crossref","unstructured":"Fiore, A.E., Finestone, S.M. & Bell, B.P. Hepatitis A vaccine. in Vaccines (eds. Plotkin, S.A., Orenstein, W.A. & Offit, P.A.) 177\u2013203 (Saunders\/Elsevier, Philadelphia, 2008).","DOI":"10.1016\/B978-1-4160-3611-1.50016-7"},{"key":"BFnm2763_CR16","doi-asserted-by":"crossref","unstructured":"Plotkin, S.A. & Vidor, E. Poliovirus vaccine\u2014inactivated. in Vaccines (eds. Plotkin, S.A., Orenstein, W.A. & Offit, P.A.) 605\u2013630 (Saunders\/Elsevier, Phildelphia, 2008).","DOI":"10.1016\/B978-1-4160-3611-1.50029-5"},{"key":"BFnm2763_CR17","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1016\/S0264-410X(01)00208-0","volume":"19","author":"AK Srivastava","year":"2001","unstructured":"Srivastava, A.K. et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19, 4557\u20134565 (2001).","journal-title":"Vaccine"},{"key":"BFnm2763_CR18","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","volume":"28","author":"TP Monath","year":"2010","unstructured":"Monath, T.P. et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28, 3827\u20133840 (2010).","journal-title":"Vaccine"},{"key":"BFnm2763_CR19","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1038\/nm1212","volume":"11","author":"HL Robinson","year":"2005","unstructured":"Robinson, H.L. & Amara, R.R. T cell vaccines for microbial infections. Nat. Med. 11, S25\u2013S32 (2005).","journal-title":"Nat. Med."},{"key":"BFnm2763_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/369648a0","volume":"369","author":"LL Lau","year":"1994","unstructured":"Lau, L.L., Jamieson, B.D., Somasundaram, T. & Ahmed, R. Cytotoxic T-cell memory without antigen. Nature 369, 648\u2013652 (1994).","journal-title":"Nature"},{"key":"BFnm2763_CR21","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1128\/JVI.74.18.8286-8291.2000","volume":"74","author":"DE Hassett","year":"2000","unstructured":"Hassett, D.E., Slifka, M.K., Zhang, J. & Whitton, J.L. Direct ex vivo kinetic and phenotypic analyses of CD8+ T cell responses induced by DNA immunization. J. Virol. 74, 8286\u20138291 (2000).","journal-title":"J. Virol."},{"key":"BFnm2763_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/eji.200425755","volume":"35","author":"K Schwarz","year":"2005","unstructured":"Schwarz, K. et al. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol. 35, 816\u2013821 (2005).","journal-title":"Eur. J. Immunol."},{"key":"BFnm2763_CR23","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/jvi.70.5.2902-2910.1996","volume":"70","author":"MK Slifka","year":"1996","unstructured":"Slifka, M.K. et al. Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes. J. Virol. 70, 2902\u20132910 (1996).","journal-title":"J. Virol."},{"key":"BFnm2763_CR24","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"BFnm2763_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4161\/hv.4.4.5751","volume":"4","author":"IJ Amanna","year":"2008","unstructured":"Amanna, I.J., Messaoudi, I. & Slifka, M.K. Protective immunity following vaccination: how is it defined? Hum. Vaccin. 4, 316\u2013319 (2008).","journal-title":"Hum. Vaccin."},{"key":"BFnm2763_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nm1261","volume":"11","author":"Y Edghill-Smith","year":"2005","unstructured":"Edghill-Smith, Y. et al. Smallpox vaccine\u2013induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11, 740\u2013747 (2005).","journal-title":"Nat. Med."},{"key":"BFnm2763_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0065-3527(03)61010-9","volume":"61","author":"KH Eckels","year":"2003","unstructured":"Eckels, K.H. & Putnak, R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv. Virus Res. 61, 395\u2013418 (2003).","journal-title":"Adv. Virus Res."},{"key":"BFnm2763_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.antiviral.2009.08.008","volume":"84","author":"IJ Amanna","year":"2009","unstructured":"Amanna, I.J. & Slifka, M.K. Wanted, dead or alive: new viral vaccines. Antiviral Res. 84, 119\u2013130 (2009).","journal-title":"Antiviral Res."},{"key":"BFnm2763_CR29","first-page":"221","volume":"114","author":"T Ng","year":"2003","unstructured":"Ng, T. et al. Equine vaccine for West Nile virus. Dev. Biol. (Basel) 114, 221\u2013227 (2003).","journal-title":"Dev. Biol. (Basel)"},{"key":"BFnm2763_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.vaccine.2008.02.009","volume":"26","author":"B Shrestha","year":"2008","unstructured":"Shrestha, B., Ng, T., Chu, H.J., Noll, M. & Diamond, M.S. The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 26, 2020\u20132033 (2008).","journal-title":"Vaccine"},{"key":"BFnm2763_CR31","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","author":"SL Giannini","year":"2006","unstructured":"Giannini, S.L. et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937\u20135949 (2006).","journal-title":"Vaccine"},{"key":"BFnm2763_CR32","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3382\/ps.0731511","volume":"73","author":"NK Neighbor","year":"1994","unstructured":"Neighbor, N.K. et al. The effect of microaerosolized hydrogen peroxide on bacterial and viral poultry pathogens. Poult. Sci. 73, 1511\u20131516 (1994).","journal-title":"Poult. Sci."},{"key":"BFnm2763_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1017\/S0031182000057309","volume":"91","author":"JY Channon","year":"1985","unstructured":"Channon, J.Y. & Blackwell, J.M. A study of the sensitivity of Leishmania donovani promastigotes and amastigotes to hydrogen peroxide. I. Differences in sensitivity correlate with parasite-mediated removal of hydrogen peroxide. Parasitology 91, 197\u2013206 (1985).","journal-title":"Parasitology"},{"key":"BFnm2763_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1472-765X.2007.02283.x","volume":"46","author":"GA DeQueiroz","year":"2008","unstructured":"DeQueiroz, G.A. & Day, D.F. Disinfection of Bacillus subtilis spore-contaminated surface materials with a sodium hypochlorite and a hydrogen peroxide-based sanitizer. Lett. Appl. Microbiol. 46, 176\u2013180 (2008).","journal-title":"Lett. Appl. Microbiol."},{"key":"BFnm2763_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3201\/eid1303.060941","volume":"13","author":"IB Gujral","year":"2007","unstructured":"Gujral, I.B., Zielinski-Gutierrez, E.C., LeBailly, A. & Nasci, R. Behavioral risks for West Nile virus disease, northern Colorado, 2003. Emerg. Infect. Dis. 13, 419\u2013425 (2007).","journal-title":"Emerg. Infect. Dis."},{"key":"BFnm2763_CR36","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","author":"E Hammarlund","year":"2003","unstructured":"Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131\u20131137 (2003).","journal-title":"Nat. Med."},{"key":"BFnm2763_CR37","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L.J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493\u2013497 (1938).","journal-title":"Am. J. Hyg."},{"key":"BFnm2763_CR38","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1189\/jlb.0806535","volume":"81","author":"HP Rau\u00e9","year":"2007","unstructured":"Rau\u00e9, H.P. & Slifka, M.K. Pivotal Advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection. J. Leukoc. Biol. 81, 1165\u20131175 (2007).","journal-title":"J. Leukoc. Biol."},{"key":"BFnm2763_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4049\/jimmunol.171.1.27","volume":"171","author":"DL Barber","year":"2003","unstructured":"Barber, D.L., Wherry, E.J. & Ahmed, R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171, 27\u201331 (2003).","journal-title":"J. Immunol."},{"key":"BFnm2763_CR40","doi-asserted-by":"publisher","first-page":"14567","DOI":"10.1073\/pnas.0800589105","volume":"105","author":"E Hammarlund","year":"2008","unstructured":"Hammarlund, E. et al. Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. Proc. Natl. Acad. Sci. USA 105, 14567\u201314572 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nm.2763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.2763","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nm.2763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:26:29Z","timestamp":1744284389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.2763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,27]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFnm2763"],"URL":"https:\/\/doi.org\/10.1038\/nm.2763","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,27]]},"assertion":[{"value":"27 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oregon Health & Science University, M.K.S. and I.J.A. have a financial interest in Naj\u00edt Technologies, a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by Oregon Health & Science University and the Integrity Program Oversight Council.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}